help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samoszuk, M. K.
Right arrow Articles by Nalcioglu, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samoszuk, M. K.
Right arrow Articles by Nalcioglu, O.
(American Journal of Pathology. 2001;159:245-251.)
© 2001 American Society for Investigative Pathology

Regular Articles

Selective Thrombosis of Tumor Blood Vessels in Mammary Adenocarcinoma Implants in Rats

Michael K. Samoszuk*, Min-Ying Su{dagger}, Ahmad Najafi{ddagger} and Orhan Nalcioglu{dagger}

From the Pathology Department,*
the Health Sciences Research Imaging Center,{dagger}
and the Brain Imaging Center,{ddagger}
University of California, Irvine, Irvine, California

Adenocarcinomas in rats and humans frequently contain perivascular, degranulating mast cells that release heparin. Protamine is a low-molecular weight, cationic polypeptide that binds avidly to heparin and neutralizes its anticoagulant properties. We hypothesized that mast-cell heparin functions as a localized anticoagulant that modulates hemostasis and blood perfusion in tumors. Consequently, systemically administered protamine should be able to neutralize the endogenous heparin within tumors, thereby inducing selective thrombosis of blood vessels within tumors. Here we demonstrate with magnetic resonance imaging (MRI) that an intravenous dose of protamine labeled with gadolinium accumulated within the parenchyma of subcutaneous implants of a mammary adenocarcinoma in Fischer 344 rats. Moreover, we show with dynamic contrast enhanced MRI that sequential intravenous doses of protamine in 12 tumor-bearing rats resulted in significantly decreased signal enhancement kinetics (blood perfusion) of the tumor. This functional impairment of MRI signal enhancement was accompanied by histological evidence of thrombosis in the blood vessels within the tumor. There was no histological evidence of thrombosis within normal liver, kidney, lung, spleen, or adjacent muscle of tumor-bearing animals that received protamine treatment or in the tumors of animals that had not been pretreated with protamine. On the basis of these results, we conclude that protamine accumulates within adenocarcinoma implants and induces selective thrombosis of blood vessels within the tumor, probably by neutralizing the endogenous heparin within tumors.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. El-Sheikh, C. Liu, H. Huang, and T. S. Edgington
A Novel Vascular Endothelial Growth Factor Heparin-binding Domain Substructure Binds to Glycosaminoglycans in Vivo and Localizes to Tumor Microvascular Endothelium
Cancer Res., December 1, 2002; 62(23): 7118 - 7123.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society for Investigative Pathology.